Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
Viking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its experimental NASH drug. However, shares drop as management did not provide any info on future plans.
Here's Why Viking Therapeutics, Inc. (VKTX) Gained But Lagged the Market Today
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.26, representing a +0.78% change from its previous close.
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
If You'd Invested $100 in Viking Therapeutics Stock 2 Years Ago, Here's How Much You'd Have Today
Viking Therapeutics develops therapies to treat obesity. Several of its drug candidates showed promising data during phase 2 trials.
Where Will Viking Therapeutics Be in 5 Years?
Viking has multiple GLP-1 drugs in development that have been generating impressive results. Given this market's potential, its financials could improve dramatically if one of its drugs is approved.
Is It Too Late to Buy Viking Therapeutics Stock?
Viking Therapeutics stock is up by a significant amount this year. It still has key catalysts on the way that investors should note.
Is Viking Therapeutics Stock a Buy?
Viking's GLP-1 inhibitor candidate has shown promise for weight loss in clinical trials. But investors should keep in mind that the company has no approved products yet.
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
With innovation, millions of retiring baby boomers, demand for better care, patent cliffs, gene-editing, massive interest in weight-loss treatments, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead. Look at weight loss stocks, like Viking Therapeutics (NASDAQ: VKTX ), for example.
